Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enzastaurin - Denovo Biopharma

Drug Profile

Enzastaurin - Denovo Biopharma

Alternative Names: DB 102; Enzastaurin hydrochloride; Kinenza; LY-317615

Latest Information Update: 14 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Denovo Biopharma; Eli Lilly
  • Class Antineoplastics; Indoles; Piperidines; Pyridines; Pyrrolidinones; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Protein kinase C beta inhibitors; Protein-serine-threonine kinase inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Discontinued Brain cancer; Breast cancer; Cancer; Colorectal cancer; Follicular lymphoma; Glioblastoma; Lung cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 14 Dec 2018 Denovo Biopharma plans a phase IIb trial for Glioblastoma (Newly diagnosed) in USA in June 2019 (PO) (NCT03776071)
  • 26 Nov 2018 Pharmacodynamics data from preclinical studies in Diffuse large B cell lymphoma released by Denovo Biopharma
  • 18 Oct 2018 Eli Lilly completes a phase II trial in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in European Union (PO) (NCT00451555)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top